Raynaud’s Phenomenon: State of the Art 1998

Meilien Ho, Jill Belch

    Research output: Contribution to journalComment/debate

    44 Citations (Scopus)

    Abstract

    Raynaud's Phenomenon (RP) is a relatively common problem which may be troublesome and difficult to treat in a minority of patients. The state of the art in 1998 focusses on three key areas: the clinical spectrum of RP; its progression and prognosis; and its treatment. RP is a systemic disease, with a multifactorial aetiology and vasospasm affects not just the digits and skin but also major organs including the heart, lungs and kidneys. It is important to distinguish primary from secondary RP. RP may predate an associated connective tissue disease by many years and markers for this include severe RP symptoms with trophic skin changes, serological abnormalities and abnormal nailfold capillaries.
    Repeated attacks of vasospasm may cause ischaemic reperfusion injury to the endothelium, resulting in a vicious and self propagating cycle of cause and effect. Nifedipine remains the "gold standard" of treatment but a number of new and promising drugs, eg relaxin, are currently under investigation. "Vasodilator-plus" drugs, with the ability to also modulate some of the haemorrheological abnormalities in RP, are the drugs that are going to have a major clinical impact on the disease and hold promise for the future.
    Original languageEnglish
    Pages (from-to)319-322
    Number of pages4
    JournalScandinavian Journal of Rheumatology
    Volume27
    Issue number5
    DOIs
    Publication statusPublished - 1998

    Fingerprint

    Raynaud Disease
    Relaxin
    Skin
    Connective Tissue Diseases
    Nifedipine
    Prednisolone
    Reperfusion Injury
    Vasodilator Agents
    Pharmaceutical Preparations
    Endothelium
    Kidney
    Lung
    Therapeutics

    Cite this

    @article{864244e93f414657b46db7f56a224318,
    title = "Raynaud’s Phenomenon: State of the Art 1998",
    abstract = "Raynaud's Phenomenon (RP) is a relatively common problem which may be troublesome and difficult to treat in a minority of patients. The state of the art in 1998 focusses on three key areas: the clinical spectrum of RP; its progression and prognosis; and its treatment. RP is a systemic disease, with a multifactorial aetiology and vasospasm affects not just the digits and skin but also major organs including the heart, lungs and kidneys. It is important to distinguish primary from secondary RP. RP may predate an associated connective tissue disease by many years and markers for this include severe RP symptoms with trophic skin changes, serological abnormalities and abnormal nailfold capillaries.Repeated attacks of vasospasm may cause ischaemic reperfusion injury to the endothelium, resulting in a vicious and self propagating cycle of cause and effect. Nifedipine remains the {"}gold standard{"} of treatment but a number of new and promising drugs, eg relaxin, are currently under investigation. {"}Vasodilator-plus{"} drugs, with the ability to also modulate some of the haemorrheological abnormalities in RP, are the drugs that are going to have a major clinical impact on the disease and hold promise for the future.",
    author = "Meilien Ho and Jill Belch",
    year = "1998",
    doi = "10.1080/03009749850154311",
    language = "English",
    volume = "27",
    pages = "319--322",
    journal = "Scandinavian Journal of Rheumatology",
    issn = "0300-9742",
    publisher = "Taylor & Francis",
    number = "5",

    }

    Raynaud’s Phenomenon : State of the Art 1998. / Ho, Meilien; Belch, Jill.

    In: Scandinavian Journal of Rheumatology, Vol. 27, No. 5, 1998, p. 319-322.

    Research output: Contribution to journalComment/debate

    TY - JOUR

    T1 - Raynaud’s Phenomenon

    T2 - State of the Art 1998

    AU - Ho, Meilien

    AU - Belch, Jill

    PY - 1998

    Y1 - 1998

    N2 - Raynaud's Phenomenon (RP) is a relatively common problem which may be troublesome and difficult to treat in a minority of patients. The state of the art in 1998 focusses on three key areas: the clinical spectrum of RP; its progression and prognosis; and its treatment. RP is a systemic disease, with a multifactorial aetiology and vasospasm affects not just the digits and skin but also major organs including the heart, lungs and kidneys. It is important to distinguish primary from secondary RP. RP may predate an associated connective tissue disease by many years and markers for this include severe RP symptoms with trophic skin changes, serological abnormalities and abnormal nailfold capillaries.Repeated attacks of vasospasm may cause ischaemic reperfusion injury to the endothelium, resulting in a vicious and self propagating cycle of cause and effect. Nifedipine remains the "gold standard" of treatment but a number of new and promising drugs, eg relaxin, are currently under investigation. "Vasodilator-plus" drugs, with the ability to also modulate some of the haemorrheological abnormalities in RP, are the drugs that are going to have a major clinical impact on the disease and hold promise for the future.

    AB - Raynaud's Phenomenon (RP) is a relatively common problem which may be troublesome and difficult to treat in a minority of patients. The state of the art in 1998 focusses on three key areas: the clinical spectrum of RP; its progression and prognosis; and its treatment. RP is a systemic disease, with a multifactorial aetiology and vasospasm affects not just the digits and skin but also major organs including the heart, lungs and kidneys. It is important to distinguish primary from secondary RP. RP may predate an associated connective tissue disease by many years and markers for this include severe RP symptoms with trophic skin changes, serological abnormalities and abnormal nailfold capillaries.Repeated attacks of vasospasm may cause ischaemic reperfusion injury to the endothelium, resulting in a vicious and self propagating cycle of cause and effect. Nifedipine remains the "gold standard" of treatment but a number of new and promising drugs, eg relaxin, are currently under investigation. "Vasodilator-plus" drugs, with the ability to also modulate some of the haemorrheological abnormalities in RP, are the drugs that are going to have a major clinical impact on the disease and hold promise for the future.

    U2 - 10.1080/03009749850154311

    DO - 10.1080/03009749850154311

    M3 - Comment/debate

    VL - 27

    SP - 319

    EP - 322

    JO - Scandinavian Journal of Rheumatology

    JF - Scandinavian Journal of Rheumatology

    SN - 0300-9742

    IS - 5

    ER -